PPARG and Alzheimer disease: We investigated the glycometabolism, lipid metabolism, and inflammatory response in MCI or AD patients after PPAR-γ agonist treatments, data are expressed as the SMD (standardized mean difference) with 95% CI, and the metabolic outcomes in studies have the same unit (FPG: mg/dL; HOMA%: -; insulin: μU/mL; TNF-α: pg/mL; IL-6: pg/mL; CRP: mg/L), as detailed in Table 3.